Deep vein thrombosis screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 15: | Line 15: | ||
==Who should not screened?== | ==Who should not screened?== | ||
* Active malignancy | |||
* Systemic lupus erythematosus | |||
* Inflammatory bowel disease | |||
* Myeloproliferative disorders | |||
===Probability scoring=== | ===Probability scoring=== | ||
Revision as of 20:28, 30 August 2011
|
Deep Vein Thrombosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Special Scenario |
|
Trials |
|
Case Studies |
|
Deep vein thrombosis screening On the Web |
|
Risk calculators and risk factors for Deep vein thrombosis screening |
Overview:Value of screening
In-spite of identifying patients at increased risk of VTE, there is no clear clinical value for screening, the following reason explains
- The strongest risk factor for VTE recurrence is the prior VTE event itself.
- After discontinuation of warfarin in VTE patients, especially where the cause was unknown, there are still at high risk of recurrence. irrespective of the presence of inherited thrombophilia.
- Anticoagulant prophylaxis is rarely recommended in asymptomatic affected family members outside of high risk situations.
Who should be screened?
Patients having any of the following, should be screened for inherited Thrombophilia
- Initial thrombosis occurring at age<50, without an immediately identified risk factor
- Positive family history of thromboembolism at age<50
- Recurrent venous thrombosis
- Thrombosis occurring in unusual vascular beds such as portal, hepatic, mesenteric, or cerebral veins
- History of warfarin-induced skin necrosis.
Who should not screened?
- Active malignancy
- Systemic lupus erythematosus
- Inflammatory bowel disease
- Myeloproliferative disorders
Probability scoring
In 2006, Scarvelis and Wells overviewed a set of clinical prediction rules for DVT,[1] on the heels of a widely adopted set of clinical criteria for pulmonary embolism.[2][3]
Wells score or criteria
(Possible score -2 to 9)
- 1) Active cancer (treatment within last 6 months or palliative) -- 1 point
- 2) Calf swelling >3 cm compared to other calf (measured 10 cm below tibial tuberosity) -- 1 point
- 3) Collateral superficial veins (non-varicose) -- 1 point
- 4) Pitting edema (confined to symptomatic leg) -- 1 point
- 5) Swelling of entire leg - 1 point
- 6) Localized pain along distribution of deep venous system -- 1 point
- 7) Paralysis, paresis, or recent cast immobilization of lower extremities -- 1 point
- 8) Recently bedridden > 3 days, or major surgery requiring regional or general anesthetic in past 12 weeks -- 1 point
- 9) Previously documented DVT -- 1 point
- 10) Alternative diagnosis at least as likely -- Subtract 2 points
Interpretation
- Score of 2 or higher - deep vein thrombosis is likely. Consider imaging the leg veins.
- Score of less than 2 - deep vein thrombosis is unlikely. Consider blood test such as d-dimer test to further rule out deep vein thrombosis.
Cases have been reported when the well score was zero [4].
References
- ↑ Scarvelis D, Wells P (2006). "Diagnosis and treatment of deep-vein thrombosis". CMAJ. 175 (9): 1087–92. PMID 17060659. Free Full Text.
- ↑ Neff MJ. ACEP releases clinical policy on evaluation and management of pulmonary embolism. American Family Physician. 2003; 68(4):759-?. Available at: http://www.aafp.org/afp/20030815/practice.html. Accessed on: December 8, 2006.
- ↑ Wells P, Anderson D, Rodger M, Ginsberg J, Kearon C, Gent M, Turpie A, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J (2000). "Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer". Thromb Haemost. 83 (3): 416–20. PMID 10744147.
- ↑ Pai RP, Kangath RV, Brown TA (2011). "Saddle pulmonary thromboembolism with zero Wells' score". Conn Med. 75 (2): 89–91. PMID 21476378.